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Abstract
In a genome-wide association study to identify loci associated with colorectal cancer (CRC) risk, we
genotyped 555,510 SNPs in 1,012 early-onset Scottish CRC cases and 1,012 controls (phase 1.) In
phase 2, we genotyped the 15,008 highest-ranked SNPs in 2,057 Scottish cases and 2,111 controls.
We then genotyped the five highest-ranked SNPs from the joint phase 1 and 2 analysis in 14,500
cases and 13,294 controls from seven populations, and identified a previously unreported association,
rs3802842 on 11q23 (OR = 1.1; P = 5.8 × 10-10), showing population differences in risk. We also
replicated and fine-mapped associations at 8q24 (rs7014346; OR = 1.19; P = 8.6 × 10-26) and 18q21
(rs4939827; OR = 1.2; P = 7.8 × 10-28). Risk was greater for rectal than for colon cancer for rs3802842
(P < 0.008) and rs4939827 (P < 0.009). Carrying all six possible risk alleles yielded OR = 2.6 (95%
CI = 1.75-3.89) for CRC. These findings extend our understanding of the role of common genetic
variation in CRC etiology.
Colorectal cancer (CRC) is the third most common cancer and fourth-leading cause of cancer
death worldwide. Lifetime risk in Western European and North American populations is
around 5%. Both genetic and environmental factors contribute to disease etiology, with about
one-third of disease variance attributed to inherited genetic factors1. Until very recently, the
defined genetic contribution to CRC comprised rare, high-penetrance variants in a few genes
(DNA mismatch repair genes2, APC, SMAD4, BMPR1A and MUTYH3). However, recent
association studies have shown that common genetic variation in the 8q24 (refs. 4-6) and 18q21
(SMAD7)7 regions also contribute to CRC risk. To explore the role of common genetic variation
in CRC etiology, we undertook a comprehensive, phased-design genome-wide association scan
(GWAS), capitalizing on Scottish population characteristics. We selected early-onset cases for
the genome-wide scan on the premise that these may be enriched for genetic contribution and
so would provide enhanced power to detect associations. Controls were matched for age, sex
and area of residence in phases 1 and 2.
In phase 1, we genotyped 1,012 early-onset CRC cases, comprising the youngest 10th
percentile of CRC age distribution in Scotland, and matched controls using Illumina
HumanHap300 and HumanHap240S arrays. We analyzed genotype data using a likelihood
ratio test (LRT)8 with 2 degrees of freedom (genotypic model) to account for additive and
dominant effects. Empirical significance thresholds were obtained by permuting case-control
status 10,000 times9. For each permutation, we retained the largest test statistic from each
chromosome and used it across all chromosomes to obtain chromosome-wise (Supplementary
Table 1 online) and genome-wide significance thresholds (Supplementary Fig. 1 online). Phase
1 test statistics with 5% empirical genome-wide significance thresholds are shown in
Supplementary Figure 2 online; none of the SNPs reached genome-wide significance
(nonminally P = 1.12 × 10-7). There was no overall inflation of the test statistic (λ = 1.003),
providing reassurance that systematic confounding factors are unlikely (Supplementary Fig.
3 online). Other process quality control measures are described in the Supplementary Note
online.
From analysis of phase 1 data, we ranked SNPs by test statistic and selected the top 15,008
SNPs (P < 0.0272) for further analysis in phase 2. We determined the number of SNPs
URLs. miRNA-target interactions, http://www.patrocles.org; CaTS, http://www.sph.umich.edu/csg/abecasis/CaTS/.
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empirically, taking into account practical and financial constraints. We genotyped these 15,008
SNPs in 2,057 cases and 2,111 controls using the Illumina iSelect platform. After accounting
for quality control measures (Supplementary Note), we included 13,450 SNP genotypes from
2,024 cases and 2,092 controls in the analysis. Joint analysis of phase 1 and 2 data again showed
that none of the SNPs reached the genome-wide significance threshold obtained by permutation
in phase 1 (Supplementary Fig. 4 and Supplementary Table 2 online). We estimated the Q
value10 of each test (proportion of false positives incurred when the test is called significant)
using phase 2 P values, and estimated the false-discovery rate to be approximately 40% for the
top 300 ranked SNPs (Supplementary Fig. 5 online).
We took the five top-ranked SNPs from joint analysis of phase 1 and 2 data, equivalent to an
empiric threshold of P < 10-5, for further analysis. In rank order by P value, the top SNPs in
the combined phase 1 and 2 data were rs7014346 (8q24), rs4939827 (18q21), rs6533603
(4q25), rs3802842 (11q23.1) and rs9951602 (18q23). Unadjusted OR estimates using binary
logistic regression in an additive genetic model are presented in Supplementary Table 2.
rs7014346 (LRT = 26.64) reached chromosome-wise significance (P < 0.05), further
replicating and refining the previous findings4-6 on the risk locus at 8q24. rs4939827 (LRT =
25.61) is located in intron 3 of SMAD7, replicating a recently reported association between this
locus and CRC7.
As the causative variants are unknown for rs7014346 (8q24) and rs4939827 (18q21), we
undertook fine mapping by tagging all polymorphic HapMap CEU SNPs around these loci in
phase 2 individuals (tagSNPs with r2 = 1 within the interval 50 kb on either side of the interval
defined by rs7014346 and rs10505477 on 8q24, and of rs4939827 and rs12953717 on 18q21).
Linkage disequilibrium (LD) plots for the 8q24, 18q23 and 11q23.1 regions are shown in
Supplementary Figure 6 online. We used data for 94 SNPs successfully genotyped at 8q24 and
96 SNPs at 18q23 for fine mapping of the respective regions (Fig. 1). The association signal
drops off sharply on either side of both rs7014346 and rs4939827. Next, we analyzed
information from HapMap using IMPUTE11 for the 11q, 8q and 18q regions to estimate SNP
genotypes that we did not type. SNPTEST was used to test for associations under a genotypic
model. These analyses (Supplementary Fig. 7 online) show that rs7842552 is the top-ranking
imputed SNP at the 8q24 locus (P = 3.84 × 10-7), rs4939827 remains the top-ranking SNP at
18q21 (P = 1.6 × 10-6) and rs3802842 indicates the peak of association at the 11q locus.
Resequencing, tumor loss-of-heterozygosity (LOH) analysis and expression studies of genes
within the regions delineated by fine mapping at 8q24 and 18q21 provided no additional insight
into pathogenicity (Supplementary Note).
In phase 3, we genotyped eight additional independent case-control collections and tested for
differences between populations. Genotyping was done using Taqman, Sequenom or Invader
technology. Subjects were from Scotland, England (Cambridge), Canada (Ontario), Germany
(Kiel and Heidelberg), Spain (Barcelona), Japan (Tokyo) and Israel (Haifa), comprising a total
of 14,500 cases and 13,294 controls (Table 1). In a meta-analysis of all data to estimate pooled
genetic effects (Table 2 and Fig. 2), we found that three of the five top-ranked associations
replicated in phase 3 (rs7014346 on 8q24, rs4939827 on 18q21 and rs3802842 on 11q23), in
agreement with our false-discovery rate estimate. Genotype counts and risk allele frequencies
across populations for the five top-ranked SNPs are shown in Supplementary Table 3 online.
We also tested for association at seven additional genotyped SNPs close to the replicated loci
(Supplementary Tables 4 and 5 online).
rs7014346 is located on 8q24 and is in high linkage disequilibrium with SNPs that we
previously reported (rs10505477 and rs6983267)4. However, rs7014346 gave the maximum
association signal in the Scottish phase 1 and 2 data. rs7014346 is 3 kb upstream of
POU5F1P1 and within intron 6 of the gene DQ515897. The association was independently
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replicated in all but the Spanish subjects (Supplementary Table 4) giving a combined P = 8.6
× 10-26. The lack of association in the Spanish cohort is most likely due to the small sample
size, as there was no significant heterogeneity for rs7014346 across populations, and
stratification tends to increase false positives rather than false negatives. Logistic regression
analysis of the combined data showed that a genotypic model fit the data significantly better
(P = 0.02) than an additive genetic model (Supplementary Table 6 online). Meta-analysis of
the pooled data (Table 2 and Fig. 2) yielded ORs for populations of European ancestry of 1.25
(95% CI = 1.18-1.32) for AG and 1.38 (95% CI = 1.28-1.48) for AA genotypes. rs7014346
showed the peak association signal because rs7842552, identified by IMPUTE fine mapping,
did not reach the same level of statistical support as rs7014346, and there was significant
heterogeneity across study populations (P = 0.026).
rs4939827 is located within intron 3 of SMAD7 on chromosome 18q21. The combined P value
for association with CRC was 7.77 × 10-28 (OR = 1.20). There was no heterogeneity among
sample sets (P = 0.34; Table 2). The association replicated in all case-control collections
individually, except the Spanish set again and the Scottish phase 3 samples (Fig. 2 and
Supplementary Table 4). There was no evidence against an additive model for this SNP
(Supplementary Table 6).
rs3802842 is located within a gene-rich region of chromosome 11q23, which adds complexity
to attempts at identifying the causative variant. Within 100 kb of rs3802842, there are four
ORFs (LOC120376, FLJ45803, C11orf53 and POU2AF1) and a sequence (rs12296076)
identified as a polymorphic binding site target for miRNAs (see URLs section below) in high
linkage disequilibrium. Of note, rs7014346 and rs3802842 were both close to genes encoding
POU transcription factors. Hence, we genotyped five additional SNPs around rs3802842,
notwithstanding that some SNPs showed only moderate statistical support (P < 0.03). However,
after genotyping in multiple sample collections, we found that rs3802842 remained the best-
supported SNP (Table 2). We observed substantial population-specific differences in risk at
the 11q23 locus, with significantly different allelic effects between the Japanese and Scottish
populations (P = 0.001) (Fig. 2). The difference in genetic effects at rs3802842 between
Europeans and Japanese remained significant (P = 0.03), even when we excluded Scottish
phase 1 data to avoid potential bias.
We did not find any evidence for gene-by-gene, sex, age, cancer stage, family history or cohort
interactions (Supplementary Tables 6 and 7 online) with rs7014346, rs4939827 or rs3802842
in the populations of European ancestry. However, there were notable site-specific differences
in risk associated with the 11q23 locus (rs3802842; P < 0.008) and the SMAD7 locus at 18q21
(rs4939827; P < 0.009) (Table 3 and Supplementary Fig. 8 online). The risk of rectal cancer
was greater than for colonic cancer for both rs3802842 and rs4939827. It should also be noted
that the differential effect on colon cancer risk and rectal cancer risk explains much of the
population differences between Japanese and Caucasian populations for rs3802842, with colon
cancer risk in particular driving the population difference.
Genome-wide association studies are beginning to unravel the genetic architecture underlying
complex disease traits. In this study, we identify a previously unreported locus on 11q23, tagged
by rs3802842, which is associated with CRC. Extending the previous observations made by
ourselves4 and others5,6 at the chromosome 8q24 locus and at the SMAD7 locus7 on 18q21,
we have fine mapped and further replicated these two associations, showing consistent effects
across multi-ethnic populations. The variants are common in the general population, with risk
allele frequencies in populations of European ancestry of 0.29, 0.37 and 0.52 for rs3802842,
rs7014346 and rs4939827, respectively. The population attributable risks (PAR) in the Scottish
population are estimated to be 6.5%, 9.6% and 3.3% for rs7014346, rs4939827 and rs3802842,
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respectively. In the Japanese population, the PAR was estimated to be 4.4% for rs 7014346
and 4% for rs4939827, primarily as a result of differences in allele frequency.
The observation that rs3802842 is associated with significantly different risk in Japanese
compared to European samples is the first evidence for a population-specific CRC
susceptibility allele. It is particularly noteworthy that the population difference is site-specific.
The Japanese population does not show the increased risk of colonic cancer associated with
rs3802842 that is observed in European populations, but it does show a similar risk of rectal
cancer at that locus.
Although we urge caution in implementing models for predicting individual risk, such
approaches incorporating multilocus genotypes could help identify high-risk subgroups within
populations. Thus, for individuals who carry all six possible risk alleles at rs7014346,
rs4939827 and rs3802842 (population frequency 0.005), the estimated OR is 2.6 (95% CI =
1.75-3.89). This underscores the potential for future risk profiling, even without identification
of the causative variant12. However, large multinational cohort studies will be needed to
validate such genetic risk predictive models.
In the context of genome-wide association studies, it is note-worthy that the associations that
replicated across populations (rs7014346, rs4939827 and rs3802842) were ranked 449, 5,965
and 11,064 in our initial scan, respectively. Hence, follow-up of the 2.7% of putative
associations from phase 1 seems appropriate. Some modeling suggests that a lower proportion
taken forward to phase 2 is sufficient (<1%)13, but power to distinguish true from false positives
using available tools (see URLs section below) may be overestimated. Study design for
genome-wide scans is evolving and, as costs reduce, genotyping of large numbers of markers
in large sample sets and avoiding phased designs altogether would be an ideal approach.
As well as providing risk estimates for population groups, identification of these loci provides
new insights into disease causation. Despite extensive resequencing, we did not identify
causative coding sequence variants in any of the genes at 8q24 (POU5F1P1, HsG57825 and
DQ515897) or 18q21 (SMAD7). It seems likely that regulatory sequence variants or position
effects underlie the associations detected here. Studies of the mechanisms by which these
genetic associations impart CRC risk could inform the development of small molecule
interventions for chemoprevention and chemotherapy.
METHODS
Study populations and genotyping
Phase 1 and 2 samples were collected in a prospective population-based study in Scotland
(1999-2006). Cases were recruited soon after confirmed diagnosis of adenocarcinoma of large
bowel (phase 1, aged ≤55 years; phase 2, aged <80 years), We genotyped individuals in phase
1 using Illumina HumanHap300 and HumanHap240S arrays on the Infinium platform, and we
genotyped individuals in phase 2 using the Illumina iSelect custom panel. For individuals in
phase 3 (described in Supplementary Methods online), we used Applied Biosystems (ABI)
TaqMan assays exclusively to genotype subjects from the Scottish, English, German, Israeli
and Spanish populations, TaqMan and Sequenom technologies for the Canadian samples and
Invader assays for the Japanese samples. Call rates and departures from Hardy-Weinberg
equilibrium (HWE) in control populations are shown in Supplementary Table 4, and quality
control measures are described in the Supplementary Note.
Statistical methods
We analyzed phase 1 data using a likelihood ratio test (LRT) with 2 degrees of freedom (d.f.)
to account for an additive and a dominant effect. Although we tested all SNPs under an allelic
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model, we did not use this for phase 2 SNP selection. Chromosome X SNPs were tested only
with 2 d.f. in females and with 1 d.f. when combining male and female samples. We used only
LRT statistics from females to select phase 2 SNPs. The mitochondrial and Y chromosome
SNPs were tested with 1 d.f. and 2 d.f., respectively. Although only the first is strictly
appropriate, only LRT with 2 d.f. was used as the selection criteria in phase 1. Thus, we applied
more stringent selection criteria for selecting phase 2 SNPs on chromosome X, Y and
mitochondrial DNA than for autosomal regions. Our approach to estimation of the false
discovery rate and permutation testing to assess genome-wide and chromosome-wise empirical
significant thresholds are both described in Supplementary Methods.
Testing differences in effects among populations
To test whether two different populations had different OR for a given SNP, we used a standar
t-test on the natural log transformation of the ORs. Under asymptotic assumptions, the InOR
is normally distributed with mean InOR and variance ( ). The statistic
, where 1 and 2 indicate the two different populations,
can be assumed to be normally distributed for large sample sizes.
Meta-analysis
We carried out the meta-analysis using the metabin option from the meta package of the R
software. We used the Mantel-Haenszel method to estimate pooled allelic effects under a fixed
effect model when there was not significant heterogeneity (PHet < 0.05). If there was significant
heterogeneity, then we used a random effects model and the DerSimonian-Laird method. The
OR was used as the summary measure. As we had used a genotypic model to select phase 3
SNPs, we also tested the same genetic model using logistic regression (fitting age, gender,
sample set and genotype) on all but the Japanese case-control set, for which the raw phenotypic
data was not available because of internal regulations in Japan. Nested models with and without
the genotypes were compared using an analysis of deviance. Interaction terms were tested in
the same fashion.
Fine mapping
LD plots for the 8q24, 18q21 and 11q23 regions are shown in Supplementary Figure 6. Detail
on fine-mapping methodology is presented in Supplementary Methods. Briefly, we selected
fine-mapping SNPs for the 8q24 and 18q21 regions using Phase 2 HapMap CEU data14.
Haploview15 was used to select SNPs to tag (r2 = 1, MAF threshold = 0.00001) from all
HapMap CEU SNPs between chromosome 8 positions 128426625 and 128543974 (50 kb
centromeric of rs10505477 (ref. 4) and 50 kb telomeric of rs7014346). Including additional
selected SNPs, there were 94 SNPs that successfully genotyped in 4,116 Scottish samples to
tag 131 alleles at r2 ≥ 0.8 (mean maximum r2 = 0.999) using Haploview 4.0 tagger15. For
18q21, we selected SNPs from the interval between positions 44657461 and 44757927 (50 kb
on either side of the interval between rs4939827 and rs12953717) and successfully genotyped
51 SNPs in 4,116 Scottish samples, tagging 64 alleles at r2 ≥ 0.8 (mean maximum r2 = 1)
(Haploview 4.0 tagger). The 11q23 locus could not be formally fine mapped. However, as it
encompasses a gene encoding a POU transcription gene family member (POU2AF1), we
selected the six top-ranked SNPs < 100 kb from POU2AF1 and two SNPs located within the
POU2AF1 gene itself. For further analysis, we used this genotyping data and HapMap data in
the program IMPUTE11. We used genotyping data from phase 1 individuals along with
HapMap data to estimate genotypes for SNPs that we did not genotype. SNPTEST was used
to test for genotype-phenotype associations under a genotypic model. Details on IMPUTE and
SNPTEST are presented in Supplementary Methods.
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Resequencing, gene expression, tumor LOH and immunohistochemistry
Resequencing focused on regions at the 8q24 and 18q21 loci delineated by fine mapping and
IMPUTE analysis. For 8q24 locus, there are three putative genes: POU5FIP1, HsG57825 and
DQ515897. As POU5FIP1 is highly homologous to other POU genes, we designed
chromosome 8-specific primers for all coding regions using a combination of primer design
packages available through the University of California Santa Cruz and Primer3
(Supplementary Methods). Amplicons were sequenced and analyzed as described16 in 168
individuals (78 cases, 90 controls). Published expression data are available5, and we also found
that POU5F1P1 is transcribed in blood leukocytes and colonic epithelium (data not shown).
The associated SNPs at the chromosome 18q21 locus were both located within the genomic
structure of SMAD7. Hence, we resequenced only exons and intron-exon boundaries of
SMAD7 in 256 individuals (166 cases and 90 controls). Available annotation and expression
data for 8q24 and 18q21 gene are described in Supplementary Methods.
We carried out LOH analysis in CRCs from up to 43 individuals heterozygous at rs7014346,
rs4939827 and rs3802842, as well as the CA repeat marker, D18S58, at the 18q21 locus. LOH
was assessed in relation to the risk allele. Tumor immunohistochemistry was done as
described2 with minor modifications in 40 tumor and normal samples for which genotypes at
rs7014346, rs4939827 and rs3802842 were previously defined.
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Fine mapping of the 8q24 and 18q23 (SMAD7) loci. Graphs show -log10P against distance.
Black dots correspond to the analysis of data generated from phase 1 and 2 individuals. Red
dots are from the analysis of data from phase 2 individuals. rslDS are provided for the SNPs
with peak evidence for association. These fine mapping data are further informed by results
shown in Supplementary Figure 7 from IMPUTE and SNPTEST analysis of the loci on
chromosomes 8q, 18q and 11q.
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Forest plot of effect size and direction for each of the three SNPs associated with CRC
(rs7014346, rs4939827 and rs3802842). Symbol size indicates the weight of the study in the
fixed effect model (the larger the symbol, the greater the weight), as in the output from the
program R. rs3802842 was stratified by ethnic group, because most of the heterogeneity
observed was due to differences between GWAS data from the Scottish and the Japanese
populations.
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Table 1
Smaples genotyped in phases 1, 2 and 3 from all populations
Population Cases Controls Total
Scotland GWAS Scotland, phase 1 981 1,002 1,983
Scotland, phase 2 2,023 2,092 4,115
Total GWAS 3,004 3,094 6,098
Replication Canada 1,175 1,184 2,359
DACHS 1,373 1,480 2,853
England 2,253 2,262 4,515
Israel 1,789 1,771 3,560
Japan 4,400 3,179 7,579
Kiel 2,169 2,145 4,314
Scotland Replication 937 941 1,878
Spain 357 297 654
Total Replication 14,453 13,259 27,712
Total samples 17, 457 16,353 33,810
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